pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture

NCT ID: NCT01392274

Last Updated: 2014-12-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

121 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-04-30

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will collect data from patients undergoing an ERCP procedure with probe-based Confocal Laser Endomicroscopy for suspicion of bile duct cancer. the objective is to evaluate the diagnostic performance of pCLE for the diagnosis of indeterminate biliary stricture when associated with other diagnostic information (standard ERCP and tissue sampling).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial aims at evaluating the performance diagnosis of pCLE for the detection of bile duct cancer, in patients with indeterminate biliary stricture when associated with other diagnostic information.

The hypothesis is that ERCP with Cellvizio probe-based endomicroscopy improves differentiation of biliary and pancreatic duct lesions versus ERCP alone or ERCP with tissue sampling, by improving the sensitivity of detection and by providing a real-time diagnosis.

Direct measures of accuracy (sensitivity, specificity, etc.) in the differentiation of malignant versus benign biliary duct lesions will be compared for the combination of ERCP alone, endomicroscopy plus ERCP imaging, and ERCP plus endomicroscopy plus tissue sampling. These information will be reviewed retrospectively by a second physician.

These presumptive diagnoses will be compared against a 12-month follow-up confirmed histopathologic endpoint (an initially-benign pathologic diagnosis will be confirmed by a 12-month follow-up). Secondary objectives include collecting patient management recommendation. Yet, effective management recommendation is left as the discretion of the physician.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cholangiocarcinoma Bile Duct Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pCLE

This trial will study only one group which will receive a standard ERCP procedure followed by pCLE

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female \> 18 years of age
* Indicated for ERCP for indeterminate bile duct stricture
* Referral patients with indeterminate biliary stricture coming in for first ERCP procedure at referral institution or
* Patients who had previous non-diagnostic tissue sampling (brushing biopsies or EUS-FNA) taken during a previous ERCP or EUS-FNA for an indeterminate biliary stricture
* Willing and able to comply with study procedures and provide written informed consent to participate in the study

Exclusion Criteria

* Subjects for whom ERCP procedures are contraindicated
* Known allergy to fluorescein dye
* Patients suffering Primary Sclerosing Cholangitis or chronic pancreatitis.
* Patients with post-transplant stricture
* If female, pregnant based on a positive hCG serum or an in vitro diagnostic test result or breast-feeding
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mauna Kea Technologies

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Adam Slivka, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburh Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yale new Haven Hospital

New Haven, Connecticut, United States

Site Status

New York presbyterian Weill Cornell Medical center

New York, New York, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Virginia Mason Medical Center

Seattle, Washington, United States

Site Status

Institut Paoli Calmettes

Marseille, , France

Site Status

Policlinico Univertitario Agostino Gemelli

Roma, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States France Italy

References

Explore related publications, articles, or registry entries linked to this study.

Slivka A, Gan I, Jamidar P, Costamagna G, Cesaro P, Giovannini M, Caillol F, Kahaleh M. Validation of the diagnostic accuracy of probe-based confocal laser endomicroscopy for the characterization of indeterminate biliary strictures: results of a prospective multicenter international study. Gastrointest Endosc. 2015 Feb;81(2):282-90. doi: 10.1016/j.gie.2014.10.009.

Reference Type DERIVED
PMID: 25616752 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MKT-2011-FOCUS

Identifier Type: -

Identifier Source: org_study_id